Skip to content
Search

Latest Stories

Ishant expects 'bowler's captain' Rahane to fill India's Kohli void

Ajinkya Rahane is a "bowler's captain" whose calm leadership will come in handy in India's bid to bounce back in the four-test series against Australia, seamer Ishant Sharma said.

Regular skipper Virat Kohli left Australia to attend the birth of his first child after India's eight-wicket humiliation in the series-opener in Adelaide inside three days.


Unlike an often-animated Kohli, Rahane maintains a low profile on the field and the bowlers are likely to be consulted more in the last three tests under him, said Ishant.

"He's very confident and I must say he's a bowler's captain," the right-arm bowler, who missed the tour with a side strain injury, told the ESPNcricinfo website.

"We've played so many times together. Whenever Virat was not there, he'd ask me 'What kind of field you want? When you want to bowl? Do you want to go on (bowling)?'

"He's a bowler's captain. He's not someone who'd say 'do this or do that'."

The 32-year-old quick said Rahane, who led India to test victories against Australia and Afghanistan in the past, often acts as a conduit between the bowlers and Kohli.

While it was nearly impossible to match Kohli's energy on the field, Rahane's composed presence could help India during pressure situations, Ishant said.

"If there's a partnership growing and it's a flat phase when fielders are just going through their motions, one player's energy level can change the scenario," he said.

"The kind of energy Virat brings to the table ... not everyone can match that.

"Jinx (Rahane) spreads calm energy in a pressure situation. There won't be any tension, he'd communicate with the bowlers very well."

The second test is scheduled in Melbourne from Dec. 26 followed by matches in Sydney and Brisbane.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less